United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

10-15mmhg) below knee closed toe lymphoedema garment female normal large dune (sigvaris britain ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

10-15mmhg) below knee closed toe lymphoedema garment female normal extra large dune (sigvaris britain ltd -

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin;   - injection (depot) - 10.8 mg - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin   excipient: polyglactin - zoladex 10.8 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.

United States - English - NLM (National Library of Medicine)

1201258 ontario inc. o/a nanz pharma - 10% povidone iodine solution usp, (1% available iodine) - topical antifungal for the treatment of athlete's foot, jock itch, and ringworm for the effective relief of burning, cracking, discomfort, redness, scaling, soreness, and chafing that is associated with jock itch.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

alphamed drug store spain - 10 viaflo bags (1000 ml) - infusion - 10 % w/v - nutrition , blood-fluids , electrolytes

New Zealand - English - Medsafe (Medicines Safety Authority)

haleon new zealand ulc - benzoyl peroxide 10% (+ overage of 19.95% =11.995%);  ;  ; benzoyl peroxide 10%{relative} (+ overage of 19.95% =11.995%) - topical gel - 10 % - active: benzoyl peroxide 10% (+ overage of 19.95% =11.995%)     excipient: citric acid monohydrate denatonium benzoate ethanol hypromellose lauromacrogol 200 perfume/fragrance alpine 6565a saponite tert-butyl alcohol water active: benzoyl peroxide 10%{relative} (+ overage of 19.95% =11.995%) excipient: citric acid ethanol hypromellose colloidal aluminium magnesium silicate lauromacrogol 200 perfume/fragrance alpine 6565a water

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - human immunoglobulin g 100 mg in 1 ml - hyqvia is an immune globulin infusion 10% (human) with a recombinant human hyaluronidase (rhuph20) indicated for the treatment of primary immunodeficiency (pi) in adults and pediatric patients two years of age and older. this includes, but is not limited to, common variable immunodeficiency (cvid), x-linked agammaglobulinemia, congenital agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies.1,2 hyqvia is indicated for the treatment of chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults. hyqvia is contraindicated in: - patients who have had a history of anaphylactic or severe systemic reactions to the administration of igg. - iga deficient patients with antibodies to iga and a history of hypersensitivity. - patients with known systemic hypersensitivity to hyaluronidase including rhuph20 of hyqvia. - patients with known systemic hypersensitivity to human albumin (in the hyaluronidase solution)]. risk summary limited human data are available to assess the presence or absence of drug-associated risk in pregnancy. in a postmarketing pregnancy study, two out of 5 infants born to mothers taking hyqvia during pregnancy had congenital abnormalities (1 cleft lip and 1 talipes calcaneovalgus). animal reproduction studies have not been conducted with the immune globulin infusion 10% (human) component of hyqvia. immune globulins increasingly cross the placenta from maternal circulation after 30 weeks of gestation. there was no evidence of teratogenicity in animal studies for rhuph20, (a component of hyqvia). the effects of antibodies to the rhuph20 on the human embryo or fetal development are unknown. it is not known whether hyqvia can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. hyqvia should be given to a pregnant woman only if clearly needed. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data human data: nine women treated with hyqvia were enrolled in a prospective, uncontrolled, open-label, multicenter post-authorization pregnancy registry. seven mothers continued hyqvia, and two mothers were treated with immune globulin other than hyqvia during the pregnancy. one mother discontinued from the registry before the expected delivery. of the eight pregnancies with known outcomes, there were eight live births. there were no specified labor or delivery complications. two out of 5 infants whose mothers took hyqvia during pregnancy had congenital abnormalities (cleft lip without cleft palate and talipes calcaneovalgus). data from the hyqvia pregnancy registry are insufficient to establish causality. the interpretation of the registry findings is limited by the small sample size, by the potential that selection bias may have increased enrollment of mothers of infants with congenital abnormalities, the absence of fetal outcomes in some exposed maternal-fetal pairs, and incomplete data on other potential etiologies. the following adverse events were identified in post-approval reports: spontaneous abortions and fetal deaths. the following congenital anomalies were identified in post-approval reports in infants whose mothers took hyqvia during pregnancy: cleft palate, atrial septal defect, ventricular septal defect, cleft lip, hypoplastic left heart syndrome (aortic atresia, mitral valve atresia), endocardial fibroelastosis, and tricuspid valve incompetence. because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. animal data: animal reproduction studies have not been conducted with immune globulin infusion 10% (human) component of hyqvia. development and reproductive toxicology studies have been conducted with rhuph20 in mice and rabbits [see nonclinical toxicology (13.2)] . no adverse effects on pregnancy were associated with anti-rhuph20 antibodies at a dose of 3 mg/kg rhuph20 in mice, which is 4800 times higher than the typical monthly human dose. no teratogenicity or signs of maternal toxicity were observed at doses up to 18 mg/kg, which is 28,800 times higher than the typical monthly human dose. doses of 9 and 18 mg/kg (14,400 and 28,800 times higher than the typical monthly human dose) in mice were associated with reduced fetal weight and an increased number of fetal resorptions. in these studies, maternal antibodies to rhuph20 were transferred to offspring in utero. the effects of antibodies to the rhuph20 component of hyqvia on the human embryo or on human fetal development are unknown. risk summary it is not known whether hyqvia can cause harm to the breastfed infant when administered to a lactating woman. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for hyqvia and any potential adverse effects on the breastfed infant from hyqvia or from the underlying maternal condition. data from the hyqvia pregnancy registry are insufficient to predict effects on the breastfed child from exposure to hyqvia through human milk. data animal data: in animal studies, maternal antibodies binding to rhuph20 were transferred to offspring during lactation. no adverse effects on pregnancy or offspring development were associated with anti-rhuph20 antibodies. the effects of antibodies that bind to rhuph20 of hyqvia transferred during human lactation are unknown. risk summary animal studies do not indicate direct or indirect harmful effects of (rhuph20) with respect to reproductive potential at the doses used for facilitating administration of ig 10% [see nonclinical toxicology (13.1)]. primary immunodeficiency (pi) the safety and effectiveness of hyqvia for the treatment of primary immunodeficiency have been established in pediatric patients 2 years and older. use of hyqvia for this indication is supported by evidence from the pivotal efficacy and safety study in 44 pediatric subjects (aged 2 to 16 years of age). results from pre-specified interim data analysis, where all subjects completed 12 months of participation (one year of observation period) in the study, indicated similar safety profiles to adults. no pediatric-specific dose requirements were necessary to achieve the desired serum igg levels. [see adverse reactions (6.1), clinical pharmacology (12.3), and clinical studies (14.1)]. safety and effectiveness of hyqvia has not been evaluated in patients <2 years of age. chronic inflammatory demyelinating polyneuropathy (cidp) the safety and effectiveness of hyqvia for the treatment of cidp have not been established in pediatric patients under the age of 18 years. primary immunodeficiency (pi) hyqvia was evaluated in 7 subjects over age 65 in the pi clinical trial. the available data are too limited to draw safety conclusions. chronic inflammatory demyelinating polyneuropathy hyqvia was evaluated in 13 subjects over age 65 in the pivotal clinical trial. no clinically significant differences in safety were observed between those 13 elderly subjects and the subjects 18 to 65 years of age. use caution when administering hyqvia to patients age 65 and over who are judged to be at increased risk of developing thrombosis and acute renal insufficiency [see boxed warning, warnings and precautions (5.2, 5.6)] . do not exceed recommended doses and administer hyqvia at the minimum dose and infusion rate practicable.

United States - English - NLM (National Library of Medicine)

laboratorios alfa srl - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - 10% dextrose dolution has value as a source of water and calories. it is used to decrease the excessive pressure of spinal brain fluid, also a scloerisng to treat varicose veins and decrease intracranial pressure. this is a single dose container and does not contain preservatives. use the solution immediately after the bottle is opened, discard the remaining one. squeeze and inspect the bottle, discard if leaks are found or if the solution contains visible and solid particles. do not administer simultaneously with blood. do not use it unless solution is clear, and seal is intact. preparation and administration 1. check for minute leaks by squeezing the container firmly. if leaks are found, discard solution as sterility may be impaired. 2. suspend container from eyelet support. 3. remove plastic protector from ports area at the bottom of container. 4. hold the bottle in vertical position and inset pyrogen free iv administration set in the outlet port. use aseptic technique to add medication warning: additives may be incompatible. to add medication before solution administration 1. prepare medication site. 2. using syringe with 19 to 22 gauge needle, puncture inlet port and inject. 3. mix solution and medication thoroughly. for high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly. to add medication during solution administration 1. close clamp on the set. 2. prepare medication site. 3. using syringe with 18 to 21 gauge needle, puncture inlet port and inject. 4. remove container from iv pole and/or turn to an upright position. 5. mix solution and medication thoroughly. 6. return container to in use position and continue administration. caution: federal law (usa) restricts this drug to use by or on the order of a licensed veterinarian.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

unique life medicines trading l.l.c united arab emirates - 10 polyethylene ampoules [5's strip x 2] in sachets x 1 ml - suspension - 10 raise to power of 8 cfu/ml - n/a-n/a

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

city medical store - sole proprietorship l.l.c dominican republic - 10’s [10x 1 litre collection bags with aps filter] - device - 10 bags - medical devices-medical devices